Summary This study was undertaken to determine the prevalence of anti-cardiolipin antibodies (ACLAs) in patients with malignancy and to investigate a possible association of ACLAs with thromboembolic events in such patients. The study included 216 patients with solid and non-solid malignancies and an age-matched control group of 88 healthy subjects. ACLA levels were measured and related to thromboembolic phenomena (diagnosed by imaging methods) that occurred within 12 months of the diagnosis of cancer. Forty-seven patients (approximately 22%) with cancer were ACLA positive as compared with only three subjects (approximately 3%) in the control group (P<0.0001). The ACLA-positive cancer patients had a significantly higher rate of thromboembolic events than ACLA-negative cancer patients: 13 of 47 (28%) vs 24 of 169 (14%), respectively (P<0.05). High titres of either IgG-ACLA or IgM-ACLA were found in 10 out of 13 ACLA-positive cancer patients with thrombotic complications, but in only 2 out of 34 cancer ACLA-positive patients without thromboembolic events (P<0.0001). In four cancer patients in whom ACLA levels were followed ACLA decreased after successful surgery/chemotherapy treatment and remained negative and thromboembolic free for 12 months of follow-up. Patients with malignancies show an increased prevalence of ACLA. Furthermore, ACLA-positive patients, mainly those with high titres, are much more prone to thromboembolic events.
The anti-phospholipid antibodies (APLAs), which include the lupus anticoagulant (LAC) and anti-cardiolipin antibodies (ACLAs), are a group of antibodies directed predominantly against negatively charged phospholipids (Hughes, 1983) . Elevated levels of APLAs have been found mainly in sera from patients with systemic lupus erythematosus (SLE) (Cervera et al., 1990) as well as other autoimmune diseases or infectious disorders and in sera from patients with the 'primary' anti-phospholipid syndrome or malignant diseases (Asherson et al., 1989a; Font et al., 1989 Font et al., , 1991 . There have been many sporadic reports of the association of APLAs, i.e. ACLAs or LAC, with malignancy such as malignant lymphoma (Mills et al., 1977; Maker et al., 1990; Asherson et al., 1991; Ciaudo et al., 1991; Conlan et al., 1991) , plasma cell dyscrasia (Duhrsen et al., 1987; Bellotti et al., 1989; Watts et al., 1989; Wisloff et al., 1991; Glaspy, 1992) , leukaemia (Duncombe et al., 1987; Donner et al., 1992) and lung, colonic, cervical, prostatic or liver cancer or thymoma (Kozlowski et al., 1987; Shaukat et al., 1990; Schleider et al., 1976; Meyrier et al., 1991; Park et al., 1991; . All these publications were case reports including fewer than 50 patients. However, the growing number of these reports suggests that the association between malignancy and antiphospholipid antibodies is not coincidental. Patients with APLAs are especially prone to recurrent episodes of venous or arterial thrombosis (Harris et al., 1984; Asherson et al., 1989b) . Although the association of vascular thrombosis with malignant diseases (Trousseau's syndrome) is well known (Sack, et al., 1977; Rickles et al., 1983) , the possible association between malignant diseases, APLAs and venous or arterial thrombosis has not been investigated, to the best of our knowledge, in a large prospective study. Our investigation is the largest study to evaluate the incidence of ACLAs in patients with malignancy, and its association with the development of thromboembolic (TE) events.
Patients and methods
Study design and subjects The subjects of this study were 241 consecutive patients with biopsy/cytology-proven neoplastic disorders who were admitted within 1 Our study thus consisted of 216 patients, whose characteristics are listed in Table I . None of them was admitted for TE events. Ninety-one of these patients were studied before the initiation of any cytotoxic or radiation treatments, whereas the remaining 125 patients were studied 3 months after such treatments were ended.
The control group included 88 age-matched subjects, all consecutively admitted to the Department of Internal Medicine 'A' at the Bnai Zion Medical Center for observation of chest pain. None of these subjects suffered from an acute coronary event, infection, chronic inflammation, malignancy, autoimmune diseases or primary anti-phospholipid syndrome or had an abnormal ECG or abnormal laboratory analysis, and they were therefore considered to be healthy. Patients were diagnosed as suffering from thromboembolism (one or more events per patient) when (1) each event occurred within 12 months after the diagnosis of malignancy and (2) it was detected by clinical symptoms and signs and was confirmed by ventilation-perfusion radionucleotide lung scan (pulmonary embolism, PE); contrast or radioisotopic phlebography or Doppler ultrasound (deep vein thrombosis, DVT); neurological signs lasting > 24 h with evidence of infarction in an anatomically consistent territory on computerised tomography (CT) or magnetic resonance imaging (MRI) (cerebral ischaemic strokes); neurological signs or symptoms lasting <24 h and fulfilling the criteria of the classification of cerebrovascular diseases of The National Institute of Neurological Disorders and Strokes (Whisnant, 1990 ) (cerebral transient ischaemic attacks, TIAs); contrast arteriography (peripheral arterial thrombosis).
Prophylactic anticoagulation All confirmed ACLA-positive TE patients were immediately started on prophylactic anticoagulation for secondary prevention of thrombosis: heparin was given intravenously for 3 days, followed by warfarin treatment [international normalized ratio (INR) 2.0-2.9].
Anti-cardiolipin antibody assay Anti-cardiolipin antibodies (ACLAs) . All ACLA determinations were performed blindly at three different runs, including other unknown sera.
Statistical analysis Data were analysed on an IBM (mainframe) computer using SPSS. The differences, regarding the various parameters, between ACLA-positive and ACLA-negative patients, and between the study and control groups, were evaluated using the chi-square or Fisher's exact test when applicable with level of significance = 0.05.
Results
Out of 216 patients with malignancies, 47 (22%) were ACLA positive, compared with only three in the control group (3%; P<0.001). Thirteen out of the 47 ACLA-positive cancer patients (28%) presented TE events within 12 months after diagnosis, whereas only 24/169 (14%) ACLA-negative cancer patients had thromboembolism (P <0.05) (see ACLA prevalence in all malignancy types in Table II) .
Out of the 47 cancer-ACLA positive patients, 31 were of IgG isotype, seven were IgM and nine were both (see Table  III ). It is evident from this table that the incidence of thromboembolism showed no correlation with low/moderate titres of ACLA, regardless of isotype (only 3/13 experienced TE events), whereas thromboembolism was present mainly in patients with high ACLA titres, since 10/13 (77%) patients with thromboembolism demonstrated high ACLA titres, whereas only 2/34 (6%) patients without thromboembolism had high titres (P<0.0001).
We did not observe any risk factors (such as family history of TE, medication, catheter usage), which could explain thromboembolism in ACLA-positive patients. No statistical difference is observed when ACLA prevalence and thromboembolism occurrence are compared with regard to type of cancer, the extent of disease and tumour burden.
In addition, no difference is observed with regard to ACLA positivity and TE events when the group of patients analysed before treatment is compared with that analysed 3 months after (data not shown). In four patients (two with colonic cancer, one with bronchogenic carcinoma and one with high-grade non-Hodgkin's lymphoma), the levels of ACLA decreased after successful surgical treatment (in the first three patients) and combination chemotherapy in the fourth patient. A decline in the ACLA titre was noted 3 months after therapy was initiated, and remained negative during 12 months of follow-up. The patient with non-Hodgkin's lymphoma developed PE and DVT when ACLA level was 145 GPL units ml-'. She was treated with low molecular weight heparin and combination chemotherapy until remission was achieved, which lasted for 12 months. During that period IgG-ACLA was within normal limits. One month before clinical and pathological relapse was observed, the ACLA titre increased again, coinciding with a massive pulmonary embolism.
In a group of five patients with elevated ACLA titres, monoclonal gammopathies of IgG isotypes were observed. Four patients had IgG myeloma and the fifth patient had non-Hodgkin's lymphoma. In four patients ACLAs were of IgG isotype; however, in one both IgG-and IgM-ACLA were elevated.
Discussion
Patients with malignancies have been shown to be at an increased risk of thromboembolism (Sack et al., 1977; Rickles et al., 1983; Goldberg et al., 1987) . The incidence of clinical TE episodes in these patients has varied from 1% to 11% (Minna, 1989) , whereas thromboembolism is more often found on post-mortem examination (Ambrus et al., 1975) .
A number of mechanisms have been proposed to explain the association of malignancy and thrombosis: activation of clotting factors (Gordon et al., 1975; Naschitz et al., 1993) , tumour interaction with vascular endothelium (Warren and Vales, 1972; Al-Mondhiry and McGarvey, 1987) and platelet activation by cancer cells (Bastida and Ordinas, 1988; Naschitz et al., 1993) . The increased presence of antiphospholipid/anti-cardiolipin antibodies in patients with cancer may be a contributory factor in the paraneoplastic development of vascular thrombosis in these patients. These antibodies are thought to predispose for thrombosis either by interacting with phospholipids on platelet membrane/vascular endothelium (Alarcon-Segovia, 1988; Alarcon-Segovia and Sanchez-Guerrero, 1989) , or by inhibiting protein C activation/prostacyclin formation by endothelial cells (Cariou et al., 1986; Carreras and Vermylen, 1982) .
A possible association between anti-phospholipid antibodies, malignancy and thrombosis has been suggested by several authors (Duhrsen et al., 1987; Kozlowski et al., 1987; Shaukat and Hughes, 1990; Gruber and Hochberg, 1991; Donner et al., 1992; Glaspy, 1992) but has not been examined in a large controlled prospective study. The present study, in which patients with 29 different types of malignancies are included, shows a high association between elevated ACLA and thrombosis in patients with cancer as compared with the control group. However, the aetiopathogenetic relationship between malignancy and ACLA is not clear. The decline in ACLA titre in four of our patients, as well as in other reported cases (Duncombe et al., 1987; Ciaudo et al., 1991) after surgical resection of the tumour or after successful chemotherapy may suggest a non-coincidental association between ACLA and cancer in these patients. Moreover, in one patient, the reappearance of ACLA was associated with relapse and recurrent thrombosis. It is not clear, however, if ACLAs serve only as a tumour marker or play a pathogenetic role in vascular thrombosis in patients with malignancy. It has been shown in our study that patients with high ACLA titres are significantly more prone to TE events than those with low ACLA titres. Moreover, the ACLA-positive cancer patients had significantly more TE events than the ACLA-negative cancer patients. These two findings seem to suggest that ACLA may play a pathogenetic role in vascular thrombosis, at least in some cancer patients. The high titre of ACLA in two patients without clinical thromboembolism might be explained by the short follow-up period.
Several mechanisms are suggested for the association between ACLA and the neoplasm:
1. Production of autoantibodies by the immune system as a response directed primarily against tumour antigens, as described in autoimmune haemolysis, Eaton-Lambert syndrome (Lang et al., 1981) or cerebellar degeneration (Greenlee and Brashear, 1983) in cancer patients. This autoimmune response could be directed against solid tumour antigens or it could be part of the well-known association between autoimmune phenomena and malignant lymphoproliferative diseases (Goldenburg et al., 1969; Miller, 1967) .
The decrease in lupus anticoagulants caused by corticosteroid treatment, as reported in a patient with inoperable adenocarcinoma of the lung (Kozlowski et al., 1987) , further supports the 'autoimmune' hypothesis. The fall in ACLA titres after either surgical resection of the tumour or chemotherapy treatment in our patients, and in other reported cases (Duncombe et al., 1987; Ciaudo et al., 1991) (Legrand et al., 1986; Schreiber and Kapp, 1986; Levine et al., 1988) . However, in our study, such an effect was not noticed. In this study we demonstrated in patients with malignancy the association of ACLA with TE. We did not analyse protein C, protein S and antithrombin III, since recent studies have shown that these factors do not correlate with the presence of ACLA in thrombotic patients (Montalban et al., 1991; Rivier et al., 1994) . In addition, these coagulation tests should always be tested off warfarin. Since all our ACLA-positive TE patients were immediately anticoagulated for secondary prevention of additional TE events, such an analysis was omitted. The question of primary prophylaxis in ACLA-positive patients is not yet conclusive and is the subject of our further study.
In conclusion, a significantly high prevalence of anticardiolipin antibodies was found in patients with various types of malignancies as compared with age-and sex-matched controls. ACLA-positive cancer patients, especially those with high ACLA levels, had a significantly higher rate of venous and/or arterial TE events than ACLA-negative cancer patients. This suggests that elevated levels of ACLA may be one of the contributory factors in the paraneoplastic TE complications occurring in patients with neoplasm.
